<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story</h1>
  <ul>
<li>Uncover how Chugai Pharmaceutical's forecasts yield a ¥8082 fair value, a 21% upside to its current price.</li>
<li>This projection is based on a 4.9% annual revenue growth rate and represents a ¥121.5 billion increase in earnings from the current ¥395.4 billion.</li>
<li>Read the full narrative on Chugai Pharmaceutical (it's free!) Chugai Pharmaceutical's outlook forecasts ¥1,381.4 billion in revenue and ¥516.9 billion in earnings by 2028.</li>
<li>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story - On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 result</li>
<li>Exploring Other Perspectives Two unique fair value estimates from the Simply Wall St Community range from ¥8,082 to ¥8,689 per share.</li>
<li>These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</li>
<li>The end of cancer?</li>
</ul>
<p><a href="https://finance.yahoo.com/news/positive-phase-3-results-orforglipron-141551068.html">Source</a> · 2025-09-08T14:15:51+00:00</p>
</body>
</html>